Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (16801)	5/16/2005 11:25:07 AM
From: Biomaven	Respond to of 52153

Yes, VEGF trap is REGN's. Part of the reason for the discrepancy between the dollars spent on pancreatic and on prostate is that many more people are diagnosed with prostate cancer and live with it. If you measure it on a "time spent living with the disease basis" the discrepancy would be not nearly as pronounced. The other reason of course is that pancreatic is pretty hopeless and prostate is often treatable - makes sense to spend dollars on diseases that you can treat. Peter